The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

The Macrocyclic and Supramolecular Chemistry Group is one of the RSC's many Interest Groups. The Interest Groups are member driven groups which exist to benefit RSC members, and the wider chemical ...

MSD is in late-stage clinical development for macrocyclic peptide drug MK-0616 (enlicitide decanoate) targeting PCSK9 in patients with hypercholesterolemia. The candidate, which is currently being ...

Mydy and colleagues studied the biosynthesis of a class of macrocyclic peptides found in plants and known for their potential use as therapeutic drugs. They identified a "fascinating new protein ...

Pasithea Therapeutics Corp., a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...